title: The role of secukinumab in the treatment of ankylosing spondylitis.
abstract: Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.
authors.affiliation: Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code OP-09, Portland, OR 97239, USA.
authors.forename: Rashmi
authors.initials: R
authors.lastname: Shah
authors.affiliation: Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code OP-09, Portland, OR 97239, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Perry
authors.affiliation: Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code OP-09, Portland, OR 97239, USA.
authors.forename: Atul
authors.initials: A
authors.lastname: Deodhar
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D051381:Rats; D012446:Sacroiliac Joint; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016176:T-Lymphocyte Subsets; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D020381:Interleukin-17; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; C555450:secukinumab
keywords: ankylosing spondylitis; axial spondyloarthritis; interleukin-17; interleukin-17 inhibitors; secukinumab